EG-2201 is a selective inhibitor of the enzyme aldose reductase, which is involved in the polyol pathway and plays a key role in the development of diabetic complications, such as neuropathy and cataracts. By inhibiting aldose reductase, EG-2201 helps reduce the accumulation of sorbitol and other harmful metabolites in tissues, potentially preventing or alleviating complications associated with diabetes. The compound’s mechanism is based on its ability to selectively block the enzyme's activity, which may also have implications for managing other conditions linked to oxidative stress and metabolic disturbances. EG-2201 is being investigated for its therapeutic potential in improving outcomes in patients with diabetic complications.
MedKoo Cat#: 145976
Name: EG-2201
CAS#: 2365471-72-1
Chemical Formula: C28H24FNO
Exact Mass: 409.1800
Molecular Weight: 409.50
Elemental Analysis: C, 82.13; H, 5.91; F, 4.64; N, 3.42; O, 3.91
The following data is based on the product molecular weight 409.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
